How much does a box of Elafibranor cost?

Elafibranor is a new drug used to treat primary biliary cholangitis (PBC). It was developed by Ipsen and marketed in the United States under the trade name "Iqirvo". As one of the targeted PBC therapeutic drugs approved by the FDA in recent years, it fills the treatment gap for some patients after ursodeoxycholic acid treatment fails. However, because it is an innovative drug, its price is relatively high, which has become the focus of widespread concern among patients.

From the perspective of market pricing, the official suggested retail price of elafibratenol in the United States is approximately 11,400 to 11,500 US dollars, and the specification is 80mg×30 tablets, which is a monthly dosage. This price is based on publicly available information on VativoRx and drug databases. The retail price at some pharmacies is as high as over $17,000 without discounts. However, by using drug discount platforms such as GoodRx or insurance reimbursement, patients can reduce the actual price paid to about 11,000 dollars, but even then, the price is still high.

Compared with similar treatmentPBC drugs, the pricing of elafibratenol is basically in the same echelon. For exampleOcaliva (obeticholic acid) and Seladelpar (trade nameLiv marli), etc., the prices are mostly between 10,000 and 13,000 US dollars per month. Therefore, although the price of Elafibranor is not low, considering that it is a new generation of PPAR receptor agonist and has shown good efficacy and tolerability in clinical trials, its price is still within a reasonable range.

In general, elafibratenol is currently mainly sold in the U.S. market and has not been launched in China and other countries. If domestic patients need to use it, they need to purchase it through overseas pharmacies or formal purchasing channels, and the cost is relatively high. For those who are looking forPBCFor patients with alternative treatment options, if financial conditions permit, elafibratenol can be used as a new treatment option. However, before official use, it is recommended to consult a doctor to evaluate the efficacy and affordability, and avoid blindly pursuing new drugs.

Reference materials:https://www.drugs.com